Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP11 | Q9NR21 | 8/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 7/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.36 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.36 |
| ▸ | PRF1 | P14222 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 5/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL279822 | 0.78 | PARP10 (0.63) | PARP11PARP10GRM5 | |
| SCHEMBL20132703 | 0.72 | KMT2A (0.46) | KDM4EMAPTSCN10A | |
| SCHEMBL25795405 | 0.71 | PARP11 (0.51) | PARP11PARP10GRM5 | |
| SCHEMBL26353996 | 0.70 | KDM4E (0.42) | KDM4EMAPTSCN10A | |
| SCHEMBL5989076 | 0.68 | DDAH1 (0.54) | KDM4EMAPTSCN10A | |
| SCHEMBL2611066 | 0.68 | PARP10 (0.63) | PARP11PARP10KDM4EGRM5 | |
| SCHEMBL18500475 | 0.67 | PARP10 (0.58) | PARP11PARP10GRM5 | |
| SCHEMBL19441071 | 0.67 | TDP1 (0.59) | KDM4EMAPTSCN10A | |
| SCHEMBL19308817 | 0.66 | KDM4E (0.37) | KDM4EMAPTSCN10A | |
| SCHEMBL17461356 | 0.65 | TDP1 (0.57) | KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11806335-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | Lilac Therapeutics, Inc. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20210128532-A1 | HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS | Lilac Therapeutics, Inc. | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11806335-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | UGDH, PGD, PNPO | PARP11 2694/4885PARP10 2086/4885KDM4E 1855/4885 |
| US-20210128532-A1 | HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS | UGDH, PGD, PNPO | PARP11 2694/4885PARP10 2086/4885KDM4E 1855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.